NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Rating of "Moderate Buy" from Analysts

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $15.50.

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $17.00 target price on shares of NeuroPace in a report on Wednesday, May 14th. HC Wainwright initiated coverage on shares of NeuroPace in a research note on Wednesday. They set a "buy" rating and a $18.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 14th. Finally, Wells Fargo & Company boosted their price target on shares of NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a research note on Thursday, January 30th.

NeuroPace Stock Performance

NPCE traded up $0.65 on Wednesday, reaching $13.11. The company had a trading volume of 570,248 shares, compared to its average volume of 159,200. NeuroPace has a 1 year low of $5.45 and a 1 year high of $18.98. The stock has a market capitalization of $429.99 million, a PE ratio of -13.11 and a beta of 2.04. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The stock has a 50-day moving average price of $12.82 and a 200-day moving average price of $12.12.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.05. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $22.52 million during the quarter, compared to analysts' expectations of $21.85 million. As a group, research analysts forecast that NeuroPace will post -1 EPS for the current fiscal year.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the transaction, the insider now directly owns 3,238,199 shares of the company's stock, valued at approximately $51,325,454.15. This trade represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.20% of the stock is currently owned by corporate insiders.

Institutional Trading of NeuroPace

Several large investors have recently modified their holdings of NPCE. BNP Paribas Financial Markets acquired a new stake in shares of NeuroPace in the fourth quarter valued at approximately $29,000. GAMMA Investing LLC acquired a new stake in shares of NeuroPace in the first quarter valued at approximately $53,000. Wells Fargo & Company MN grew its position in shares of NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after purchasing an additional 2,279 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of NeuroPace by 106.3% in the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company's stock valued at $84,000 after purchasing an additional 6,181 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in shares of NeuroPace in the fourth quarter valued at approximately $103,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.